| Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More | Frank Vinluan | 10/09/20 | National |
| Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B | Frank Vinluan | 10/05/20 | New York |
| Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity | Mandy Jackson | 10/02/20 | National |
| Galecto Picks Up $64M as Plans for Fibrosis Clinical Trials Move Forward | Frank Vinluan | 09/25/20 | Europe |
| Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More | Frank Vinluan | 09/25/20 | National |
| Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs | Frank Vinluan | 09/24/20 | Boston |
| Gilead Sciences Places $120M Bet on a Jounce Therapeutics Cancer Drug | Frank Vinluan | 09/01/20 | San Francisco |
| Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More | Frank Vinluan | 08/28/20 | National |
| Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More | Sarah de Crescenzo | 08/21/20 | National |
| Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy | Sarah de Crescenzo | 08/17/20 | New York |
| Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More | Frank Vinluan | 08/14/20 | National |
| MorphoSys, Incyte Get Early FDA Nod for Antibody Alternative to CAR-T | Frank Vinluan | 08/03/20 | Europe |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| Freeline Therapeutics and Checkmate Pharma Make Opening IPO Moves | Frank Vinluan | 07/21/20 | Europe |
| Ovid Licenses European Rights to Lead Rare Disease Drug to Angelini Pharma | Sarah de Crescenzo | 07/13/20 | Boston |
| Bio Roundup: Blackstone’s Billions, Biogen Finishes Filing, Novavax at “Warp Speed” & More | Sarah de Crescenzo | 07/10/20 | National |
| On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO | Sarah de Crescenzo | 07/06/20 | San Francisco |
| Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases | Frank Vinluan | 07/06/20 | Boston |
| Invitae Makes a Precision Oncology Push With $886M Deal for ArcherDx | Frank Vinluan | 06/22/20 | San Francisco |
| Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better | Frank Vinluan | 06/19/20 | Raleigh Durham |
| Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer | Sarah de Crescenzo | 06/17/20 | San Diego |
| Legend Biotech’s Upsized IPO Lands $424M for Multiple Myeloma Drug | Frank Vinluan | 06/05/20 | New York |
| Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
| Atlas Venture Raises $400M Fund to Seed Another New Set of Biotechs | Sarah de Crescenzo | 06/05/20 | Boston |
| Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs | Sarah de Crescenzo | 05/29/20 | Boston |
| After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO | Frank Vinluan | 05/29/20 | Boston |
| Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More | Sarah de Crescenzo | 05/29/20 | National |
| Gilead Gains Foothold in Solid Tumors With $375M, 10-Year Arcus Bio Pact | Frank Vinluan | 05/27/20 | San Francisco |
| Vividion Gets $135M in Collaboration With Roche on Protein Degradation | Sarah de Crescenzo | 05/20/20 | San Diego |
| Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More | Sarah de Crescenzo | 05/15/20 | National |
